Ocugen Inc Stock Performance
| OCGN Stock | USD 0.92 0.01 1.10% |
The company holds a Beta of 1.91, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ocugen will likely underperform. At this point, Ocugen Inc has a negative expected return of -0.44%. Please make sure to check Ocugen's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Ocugen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ocugen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:60 | Dividend Date 2019-09-30 | Last Split Date 2019-09-30 |
1 | NASDAQ OCGN Investor Notice Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation | 09/16/2024 |
2 | Ocugen to Host Conference Call on Friday, November 8 at 830 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results | 10/17/2024 |
3 | Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 | 10/28/2024 |
4 | Ocugen Secures 30 Million in Debt Funding | 11/07/2024 |
5 | Ocugen soars 19 percent this week, taking one-year gains to 193 | 11/08/2024 |
6 | Ocugens Buy Rating Reiterated at HC Wainwright | 11/14/2024 |
7 | Ocugen Announces Compelling Preliminary Data for OCU410--a Single Dose Novel Modifier Gene ... | 11/19/2024 |
8 | Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment ofABCA4-Associ... | 11/20/2024 |
| Begin Period Cash Flow | 77.6 M |
Ocugen |
Ocugen Relative Risk vs. Return Landscape
If you would invest 129.00 in Ocugen Inc on August 28, 2024 and sell it today you would lose (37.00) from holding Ocugen Inc or give up 28.68% of portfolio value over 90 days. Ocugen Inc is currently does not generate positive expected returns and assumes 4.1126% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Ocugen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ocugen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ocugen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ocugen Inc, and traders can use it to determine the average amount a Ocugen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.108
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OCGN |
Estimated Market Risk
| 4.11 actual daily | 36 64% of assets are more volatile |
Expected Return
| -0.44 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ocugen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ocugen by adding Ocugen to a well-diversified portfolio.
Ocugen Fundamentals Growth
Ocugen Stock prices reflect investors' perceptions of the future prospects and financial health of Ocugen, and Ocugen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ocugen Stock performance.
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (11.67) % | ||||
| Current Valuation | 236.74 M | ||||
| Shares Outstanding | 291.32 M | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 6.61 X | ||||
| Price To Sales | 57.16 X | ||||
| Revenue | 6.04 M | ||||
| Gross Profit | (49.76 M) | ||||
| EBITDA | (64.83 M) | ||||
| Net Income | (63.08 M) | ||||
| Cash And Equivalents | 101.6 M | ||||
| Cash Per Share | 0.46 X | ||||
| Total Debt | 6.94 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 7.21 X | ||||
| Book Value Per Share | 0.16 X | ||||
| Cash Flow From Operations | (62.05 M) | ||||
| Earnings Per Share | (0.19) X | ||||
| Market Capitalization | 268.66 M | ||||
| Total Asset | 64.55 M | ||||
| Retained Earnings | (286.17 M) | ||||
| Working Capital | 25.88 M | ||||
| Current Asset | 17.53 M | ||||
| Current Liabilities | 4.21 M | ||||
About Ocugen Performance
By examining Ocugen's fundamental ratios, stakeholders can obtain critical insights into Ocugen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Ocugen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.98) | (1.03) | |
| Return On Capital Employed | (1.38) | (1.45) | |
| Return On Assets | (0.98) | (1.03) | |
| Return On Equity | (1.56) | (1.48) |
Things to note about Ocugen Inc performance evaluation
Checking the ongoing alerts about Ocugen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ocugen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ocugen Inc generated a negative expected return over the last 90 days | |
| Ocugen Inc has some characteristics of a very speculative penny stock | |
| Ocugen Inc has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 6.04 M. Net Loss for the year was (63.08 M) with loss before overhead, payroll, taxes, and interest of (49.76 M). | |
| Ocugen Inc currently holds about 101.6 M in cash with (62.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.46. | |
| Ocugen Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment ofABCA4-Associated Retinopathies including Stargardt Disease |
- Analyzing Ocugen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ocugen's stock is overvalued or undervalued compared to its peers.
- Examining Ocugen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ocugen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ocugen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ocugen's stock. These opinions can provide insight into Ocugen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.19) | Revenue Per Share 0.018 | Quarterly Revenue Growth 1.353 | Return On Assets (0.48) | Return On Equity (1.03) |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.